Heron Therapeutics, Inc. (HRTX)

NASDAQ: HRTX · IEX Real-Time Price · USD
2.84
-0.06 (-2.07%)
Feb 3, 2023, 4:00 PM EST - Market closed
-2.07%
Market Cap 337.64M
Revenue (ttm) 98.30M
Net Income (ttm) -216.80M
Shares Out 118.89M
EPS (ttm) -2.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,741,097
Open 2.83
Previous Close 2.90
Day's Range 2.80 - 3.07
52-Week Range 2.19 - 9.45
Beta 0.83
Analysts Buy
Price Target 10.63 (+274.3%)
Earnings Date Feb 27, 2023

About HRTX

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycli... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Aug 26, 1987
Employees 302
Stock Exchange NASDAQ
Ticker Symbol HRTX
Full Company Profile

Financial Performance

In 2021, HRTX's revenue was $86.35 million, a decrease of -2.59% compared to the previous year's $88.64 million. Losses were -$220.68 million, -2.90% less than in 2020.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for HRTX stock is "Buy." The 12-month stock price forecast is $10.63, which is an increase of 274.30% from the latest price.

Price Target
$10.63
(274.30% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Looking Back At The 10 Most Shorted Stocks Of December 2022

Shorting stocks is still a viable strategy for experienced investors who are active in the stock market. Here is a look back at the most shorted stocks of December 2022.

3 weeks ago - Forbes

Heron Therapeutics Highlights Progress in Acute Care and Oncology Care Franchises

- Preliminary Annual Net Product Sales Across the Company Grew 24% to $106.7 Million in 2022, Compared to Annual Net Product Sales in 2021 - - Preliminary Fourth-Quarter 2022 Net Product Sales for ZYN...

3 weeks ago - PRNewsWire

Heron Therapeutics Announces Filing of an Efficacy Supplement for ZYNRELEF® and Provision in Newly Passed Congressional Bill Anticipated to Provide Separate Reimbursement Outside of the Packaged Surgical Payment for ZYNRELEF

- Supplemental New Drug Application Submitted Requesting Expansion of Indication to Broadly Cover Soft Tissue and Orthopedic Surgical Procedures - - Omnibus Spending Bill (H.R. 2617) Includes Provisio...

1 month ago - PRNewsWire

Heron Therapeutics Announces Virtual Presentation at Evercore ISI 5th Annual HealthCONx Conference

SAN DIEGO , Nov. 21, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treat...

2 months ago - PRNewsWire

7 Penny Stocks to Buy for 10-Bagger Returns

Some good news is finally starting to creep into the markets with inflation easing in October. However, GDP growth remains a concern.

Other symbols: KGCPSNYRIGSNDLSOLOTLRY
2 months ago - InvestorPlace

Heron Therapeutics (HRTX) Reports Q3 Loss, Tops Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 2.56% and 1.27%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Highlights Recent Corporate Updates

- APONVIE™ approval by FDA, U.S. launch planned for Q1 2023 – - ZYNRELEF ®  unit demand grew 18% over prior quarter in Q3 2022 – - Oncology Care Franchise net product sales grew 13% over prior year in...

3 months ago - PRNewsWire

Hurry! 7 Pitiful Stocks to Sell Before 2022 Ends

When it comes to certain stocks to sell, being overly optimistic can become a liability. No, this is not a popular topic by any means, usually arousing anger among the investing faithful.

Other symbols: AIUARECGOLMARKRCLSRNE
3 months ago - InvestorPlace

Heron Therapeutics to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022

SAN DIEGO , Nov. 1, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatm...

3 months ago - PRNewsWire

Top 10 Most Shorted Stocks List For October 2022

Shorting stocks has become an interest of many modern investors, particularly after the meme stock craze that started in 2020. Here are the ten most shorted stocks right now.

4 months ago - Forbes

4 No-Brainer Penny Stocks to Buy if You Have Money to Invest

Penny stocks have always fascinated investors. That's because higher-risk, lower-priced penny stocks to buy can be portfolio game-changers.

Other symbols: BITFCRONMNSO
4 months ago - InvestorPlace

7 Unknown Biotech Stocks That Could Rocket in 2023

Investing in early-stage or unknown biotech stocks can be likened to investing in cryptocurrency projects. If the project developments are positive, returns can be multi-folds in a short time.

4 months ago - InvestorPlace

Heron Therapeutics Announces U.S. FDA Approval of APONVIE™ (HTX-019) for the Prevention of Postoperative Nausea and Vomiting (PONV)

- APONVIE is the first and only intravenous (IV) formulation of a substance P/neurokinin-1 (NK1) receptor antagonist indicatedfor PONV - - Delivered via a single 30-second IV injection, APONVIE has de...

5 months ago - PRNewsWire

All You Need to Know About Heron Therapeutics (HRTX) Rating Upgrade to Buy

Heron Therapeutics (HRTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

5 months ago - Zacks Investment Research

How Much Upside is Left in Heron Therapeutics (HRTX)? Wall Street Analysts Think 91%

The average of price targets set by Wall Street analysts indicates a potential upside of 90.6% in Heron Therapeutics (HRTX). While the effectiveness of this highly sought-after metric is questionable,...

6 months ago - Zacks Investment Research

Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -10% and 11.98%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Heron Therapeutics Announces $76.5 Million Private Placement Financing

SAN DIEGO , Aug. 9, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing ...

6 months ago - PRNewsWire

Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Highlights Recent Corporate Updates

- ZYNRELEF® launch trend continues at a strong pace with sequential quarterly product sales increase of 140% and unit demand increase of 47% - - Oncology Care Franchise net product sales grew 12% over...

6 months ago - PRNewsWire

Heron Therapeutics to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022

SAN DIEGO , Aug. 2, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing ...

6 months ago - PRNewsWire

7 Biotech Stocks to Buy for Q3

These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential. The post 7 Biotech Stocks to Buy for Q3 appeared first on I...

7 months ago - InvestorPlace

Heron Therapeutics to cut about one-third of its workforce as part of cost-cutting plan

Heron Therapeutics Inc. HRTX, +3.26% said Thursday it will lay off about one-third of its workforce as part of a restructuring expected to save $43 million a year. The biotechnology company's stock wa...

7 months ago - Market Watch

Heron Therapeutics Announces Restructuring and Cost Reduction Plan to Address Market Dynamics and Prepare for Long-Term Sustainability

- Changes result in annualized cost savings of $43M, extending the cash runway; Company is continuing to reduce external spend -  - Reduces organization headcount by 34% - - Priorities remain on comme...

7 months ago - PRNewsWire

Heron Therapeutics Announces Publication Showing ZYNRELEF® as the Foundation of a Perioperative Non-Opioid Multimodal Analgesic Regimen Reduced Severe Pain and Opioid Use in Patients Undergoing Total Knee Arthroplasty

SAN DIEGO , June 14, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing...

8 months ago - PRNewsWire

Heron Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference

SAN DIEGO , May 26, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing ...

9 months ago - PRNewsWire

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Heron Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

NEW YORK , May 26, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim ...

9 months ago - PRNewsWire